Free Trial
NASDAQ:SUPN

Supernus Pharmaceuticals (SUPN) Stock Price, News & Analysis

Supernus Pharmaceuticals logo
$31.79 +0.11 (+0.35%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$31.70 -0.09 (-0.28%)
As of 05/30/2025 04:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Supernus Pharmaceuticals Stock (NASDAQ:SUPN)

Key Stats

Today's Range
$31.41
$31.90
50-Day Range
$30.29
$33.43
52-Week Range
$25.53
$40.28
Volume
750,724 shs
Average Volume
482,798 shs
Market Capitalization
$1.78 billion
P/E Ratio
29.71
Dividend Yield
N/A
Price Target
$36.00
Consensus Rating
Hold

Company Overview

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

Supernus Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
47th Percentile Overall Score

SUPN MarketRank™: 

Supernus Pharmaceuticals scored higher than 47% of companies evaluated by MarketBeat, and ranked 616th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Supernus Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Supernus Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about Supernus Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Supernus Pharmaceuticals are expected to decrease by -39.50% in the coming year, from $2.38 to $1.44 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Supernus Pharmaceuticals is 29.71, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.20.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Supernus Pharmaceuticals is 29.71, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.85.

  • Price to Book Value per Share Ratio

    Supernus Pharmaceuticals has a P/B Ratio of 1.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Supernus Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    7.89% of the float of Supernus Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Supernus Pharmaceuticals has a short interest ratio ("days to cover") of 7.1.
  • Change versus previous month

    Short interest in Supernus Pharmaceuticals has recently increased by 5.29%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Supernus Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Supernus Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.89% of the float of Supernus Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Supernus Pharmaceuticals has a short interest ratio ("days to cover") of 7.1.
  • Change versus previous month

    Short interest in Supernus Pharmaceuticals has recently increased by 5.29%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Supernus Pharmaceuticals has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Supernus Pharmaceuticals this week, compared to 5 articles on an average week.
  • MarketBeat Follows

    2 people have added Supernus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
Receive SUPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Supernus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SUPN Stock News Headlines

White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
Supernus Announces Paragraph IV ANDA Filings for Qelbree®
See More Headlines

SUPN Stock Analysis - Frequently Asked Questions

Supernus Pharmaceuticals' stock was trading at $36.16 at the beginning of 2025. Since then, SUPN stock has decreased by 12.1% and is now trading at $31.79.
View the best growth stocks for 2025 here
.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) issued its earnings results on Monday, November, 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.44 by $0.25. The business's quarterly revenue was up 14.2% on a year-over-year basis.
Read the conference call transcript
.

Top institutional investors of Supernus Pharmaceuticals include Vanguard Group Inc. (11.01%), Armistice Capital LLC (9.28%), Stephens Investment Management Group LLC (3.11%) and GW&K Investment Management LLC (2.48%). Insiders that own company stock include Jack A Khattar, Tami Tillotson Martin, Frederick M Hudson, Georges Gemayel, Padmanabh P Bhatt, Frank Mottola and Jonathan Rubin.
View institutional ownership trends
.

Shares of SUPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Supernus Pharmaceuticals investors own include American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), Humana (HUM) and AUO (AUOTY).

Company Calendar

Last Earnings
11/04/2024
Today
5/30/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:SUPN
Employees
580
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$36.00
High Stock Price Target
$36.00
Low Stock Price Target
$36.00
Potential Upside/Downside
+13.2%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
29.71
Forward P/E Ratio
13.36
P/E Growth
N/A
Net Income
$1.32 million
Pretax Margin
11.12%

Debt

Sales & Book Value

Annual Sales
$668.00 million
Cash Flow
$1.46 per share
Price / Cash Flow
21.83
Book Value
$16.87 per share
Price / Book
1.88

Miscellaneous

Free Float
50,084,000
Market Cap
$1.78 billion
Optionable
Optionable
Beta
0.74

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:SUPN) was last updated on 5/31/2025 by MarketBeat.com Staff
From Our Partners